PUBLISHER: Lucintel | PRODUCT CODE: 1263963
PUBLISHER: Lucintel | PRODUCT CODE: 1263963
Liquid Biopsy Market Trends and Forecast
The future of the global liquid biopsy market looks promising with opportunities in reference laboratories, hospitals and physician laboratories, and academic and research centers. The global liquid biopsy market is expected to reach an estimated $8.6 billion by 2027 with a CAGR of 14.5% from 2022 to 2027. The major drivers for this market are the increasing prevalence of cancer, preference for non-invasive procedures, and increasing need of early detection of high precision diseases in real time.
Emerging Trends in Liquid Biopsy Market
Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.
A total of 163 figures / charts and 129 tables are provided in this 264-page report to help in your business decisions. Sample figures with some insights are shown below.
Liquid Biopsy Market by Segment
In this market, therapy selection is the largest clinical application market, and circulating tumor DNA is the largest circulating biomarker segment. Growth in various segments of the liquid biopsy market are shown in the figure below.
Liquid Biopsy Market by Product [Value ($M) from 2016 to 2027]:
Liquid Biopsy Market by Circulating Biomarker [Value ($M) from 2016 to 2027]:
Liquid Biopsy Market by Application [Value ($M) from 2016 to 2027]:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Other Cancers
Liquid Biopsy Market by Clinical Application [Value ($M) from 2016 to 2027]:
Liquid Biopsy Market by End Use [Value ($M) from 2016 to 2027]:
Liquid Biopsy Market by Region [Value ($M) from 2016 to 2027]:
US
Canada
Mexico
United Kingdom
France
Germany
Italy
Spain
China
Japan
India
Brazil
List of Liquid Biopsy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, liquid biopsy companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the liquid biopsy companies profiled in this report include-
Liquid Biopsy Market Insights
Features of the Global Liquid Biopsy Market
FAQ
Q1. What is theliquid biopsy marketsize?
Answer:The global liquid biopsy market is expected to reach an estimated $10.4 billion by 2026.
Q2. What is the growth forecast for theliquid biopsy market?
Answer:The global liquid biopsy market is expected to grow at a CAGR of ~17% from 2020 to 2026.
Q3. What are the major drivers influencing the growth of theliquid biopsy market?
Answer: The major drivers for this market are increasing prevalence of cancer, preference for non-invasive procedures, and increasing need for early detection of high precision diseases in real time.
Q4. What are the major clinical applications of theliquid biopsy market?
Answer:Early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring are the major clinical application segments of liquid biopsy.
Q5. What are the emerging trends in theliquid biopsy market?
Answer:Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.
Q6. Who are the keyliquid biopsy companies?
Answer:Some of the key liquid biopsy companies are as follows:
Q7.Which will be the largestcirculating biomarker segment of theliquid biopsy marketin the future?
Answer: Lucintel forecasts that circulating tumor DNA (ctDNA) will remain the largest segment, and it is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in the early stage.
Q8: Inliquid biopsy market, which region is expected to be the largest in the next five years?
Answer:Asia Pacific is expected to be the largest region over the next five years.
Q9. Do we receive customization in this report?
Answer:Yes, Lucintel provides 10% customization without any additional cost.